In the second week after the SEC opened we saw a number of launches and two billion-dollar biotechs, Alector (ALEC) and Gossamer Bio (GOSS), price their IPOs. Another biotech, Harpoon Therapeutics (HARP),...read more
Harpoon Therapeutics, a Phase 1 biotech developing T cell immunotherapies for various cancers, raised $76 million by offering 5.4 million shares at $14, the midpoint of the $13 to $15 range. Harpoon Therapeutics plans to list on the Nasdaq under the symbol...read more
Four IPOs plan to raise $523 million in the week ahead. Biotechs are still a strong force in the IPO market with three early-stage immunotherapy plays on the docket, including two with proposed billion-dollar valuations. A micro-cap Florida bank rounds out the...read more
Harpoon Therapeutics, a Phase 1 biotech developing immunotherapies for various cancers, announced terms for its IPO on Tuesday. The South San Francisco, CA-based company plans to raise $76 million by offering 5.4 million shares at a price range of $13 to...read more
US IPO Weekly Recap: Two billion-dollar biotechs cap a mixed week for biotech IPOs
In the second week after the SEC opened we saw a number of launches and two billion-dollar biotechs, Alector (ALEC) and Gossamer Bio (GOSS), price their IPOs. Another biotech, Harpoon Therapeutics (HARP),...read more
Cancer biotech Harpoon Therapeutics prices $76 million IPO at $14 midpoint
Harpoon Therapeutics, a Phase 1 biotech developing T cell immunotherapies for various cancers, raised $76 million by offering 5.4 million shares at $14, the midpoint of the $13 to $15 range. Harpoon Therapeutics plans to list on the Nasdaq under the symbol...read more
US IPO Week Ahead: 2 billion-dollar biotechs in a 4-IPO week
Four IPOs plan to raise $523 million in the week ahead. Biotechs are still a strong force in the IPO market with three early-stage immunotherapy plays on the docket, including two with proposed billion-dollar valuations. A micro-cap Florida bank rounds out the...read more
Immuno-oncology biotech Harpoon Therapeutics sets terms for $76 million IPO
Harpoon Therapeutics, a Phase 1 biotech developing immunotherapies for various cancers, announced terms for its IPO on Tuesday. The South San Francisco, CA-based company plans to raise $76 million by offering 5.4 million shares at a price range of $13 to...read more